Cyclopharm Limited
ASX CYC.AX
Cyclopharm Limited Price to Earnings Ratio (P/E) on February 05, 2025: -49.98
-
Cyclopharm Limited 52-week high Price to Earnings Ratio (P/E) is -30.34 on November 26, 2024, which is 39.29% above the current Price to Earnings Ratio (P/E).
-
Cyclopharm Limited 52-week low Price to Earnings Ratio (P/E) is -52.04 on February 04, 2025, which is -4.12% below the current Price to Earnings Ratio (P/E).
-
Cyclopharm Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is -37.17.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
Don’t Miss A Beat
| CEO | Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDM |
| IPO Date | Jan. 17, 2007 |
| Location | Australia |
| Headquarters | 1 The Crescent |
| Employees | 87 |
| Sector | Healthcare |
| Industries | |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Past 5 years
USD 0.74
StockViz Staff
February 7, 2025
Any question? Send us an email